drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00106 | DB00215 | 618 | 1,230 | [
"DDInter4",
"DDInter388"
] | Abarelix | Citalopram | Synthetic decapeptide antagonist to gonadotropin releasing hormone (GnRH). It is marketed by Praecis Pharmaceuticals as Plenaxis. Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market. | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] C... | Major | 2 | [
[
[
618,
25,
1230
]
],
[
[
618,
25,
318
],
[
318,
40,
1230
]
],
[
[
618,
24,
384
],
[
384,
62,
1230
]
],
[
[
618,
23,
112
],
[
112,
... | [
[
[
"Abarelix",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Citalopram"
]
],
[
[
"Abarelix",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Escitalopram"
],
[
"Escitalopram",
"{u} (... | Abarelix may lead to a major life threatening interaction when taken with Escitalopram and Escitalopram (Compound) resembles Citalopram (Compound)
Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a minor interaction that can limit clinical effe... |
DB00468 | DB09075 | 1,424 | 498 | [
"DDInter1557",
"DDInter621"
] | Quinine | Edoxaban | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to r... | Major | 2 | [
[
[
1424,
25,
498
]
],
[
[
1424,
24,
109
],
[
109,
24,
498
]
],
[
[
1424,
24,
116
],
[
116,
63,
498
]
],
[
[
1424,
64,
1230
],
[
1230,
... | [
[
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edoxaban"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duloxetine"
],
[
"Duloxetine",
... | Quinine may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131 and Iodide I-131... |
DB00801 | DB01377 | 1,563 | 1,283 | [
"DDInter850",
"DDInter1119"
] | Halazepam | Magnesium oxide | Halazepam is a _benzodiazepine_ derivative drug exerting anxiolytic, anticonvulsant, sedative, a muscle relaxing effects.[A1212, A178114] It has been shown to be less toxic than chlordiazepoxide or diazepam. This drug is no longer marketed in the United States, and was withdrawn by _Schering_, its manufacturer, in 2009... | Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. | Minor | 0 | [
[
[
1563,
23,
1283
]
],
[
[
1563,
1,
905
],
[
905,
23,
1283
]
],
[
[
1563,
40,
1174
],
[
1174,
23,
1283
]
],
[
[
1563,
63,
752
],
[
752,
... | [
[
[
"Halazepam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium oxide"
]
],
[
[
"Halazepam",
"{u} (Compound) resembles {v} (Compound)",
"Lorazepam"
],
[
"Lorazepam",
"{u} may cause a minor in... | Halazepam (Compound) resembles Lorazepam (Compound) and Lorazepam may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
Halazepam (Compound) resembles Temazepam (Compound) and Temazepam may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide
... |
DB00687 | DB00867 | 870 | 1,052 | [
"DDInter747",
"DDInter1606"
] | Fludrocortisone | Ritodrine | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Adrenergic beta-agonist used to control premature labor. | Minor | 0 | [
[
[
870,
23,
1052
]
],
[
[
870,
63,
1523
],
[
1523,
40,
1052
]
],
[
[
870,
1,
175
],
[
175,
23,
1052
]
],
[
[
870,
1,
1220
],
[
1220,
... | [
[
[
"Fludrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ritodrine"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Labetalol"
],
... | Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Labetalol (Compound) resembles Ritodrine (Compound)
Fludrocortisone (Compound) resembles Triamcinolone (Compound) and Triamcinolone may cause a minor interaction that can limit clinical effects when taken with ... |
DB00637 | DB01182 | 1,557 | 371 | [
"DDInter128",
"DDInter1534"
] | Astemizole | Propafenone | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. | Moderate | 1 | [
[
[
1557,
24,
371
]
],
[
[
1557,
63,
847
],
[
847,
1,
371
]
],
[
[
1557,
40,
704
],
[
704,
1,
371
]
],
[
[
1557,
24,
675
],
[
675,
4... | [
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propafenone"
]
],
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atomoxetine"
],
[
... | Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Atomoxetine and Atomoxetine (Compound) resembles Propafenone (Compound)
Astemizole (Compound) resembles Fentanyl (Compound) and Fentanyl (Compound) resembles Propafenone (Compound)
Astemizole may cause a moderate interaction that... |
DB01124 | DB08907 | 1,411 | 1,344 | [
"DDInter1828",
"DDInter280"
] | Tolbutamide | Canagliflozin | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
1411,
24,
1344
]
],
[
[
1411,
24,
549
],
[
549,
1,
1344
]
],
[
[
1411,
21,
28680
],
[
28680,
60,
1344
]
],
[
[
1411,
62,
1103
],
[
110... | [
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
... | Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Tolbutamide (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Canagliflozin (Compound)
Tolbutamide may cause a minor interactio... |
DB01599 | DB11057 | 1,232 | 720 | [
"DDInter1523",
"DDInter1223"
] | Probucol | Mineral oil | A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993). | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced b... | Moderate | 1 | [
[
[
1232,
24,
720
]
],
[
[
1232,
24,
927
],
[
927,
63,
720
]
],
[
[
1232,
63,
1151
],
[
1151,
24,
720
]
],
[
[
1232,
25,
1069
],
[
1069,
... | [
[
[
"Probucol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Probucol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
... | Probucol may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Probucol may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitini... |
DB00446 | DB01066 | 597 | 1,462 | [
"DDInter351",
"DDInter316"
] | Chloramphenicol | Cefditoren | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Cefditoren is an oral third-generation cephalosporin. It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma. | Moderate | 1 | [
[
[
597,
24,
1462
]
],
[
[
597,
24,
1403
],
[
1403,
40,
1462
]
],
[
[
597,
24,
1392
],
[
1392,
1,
1462
]
],
[
[
597,
63,
149
],
[
149,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefditoren"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefepime"
],
... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Cefepime and Cefepime (Compound) resembles Cefditoren (Compound)
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Cefadroxil and Cefadroxil (Compound) resembles Cefditoren (Comp... |
DB00434 | DB01242 | 13 | 1,237 | [
"DDInter459",
"DDInter410"
] | Cyproheptadine | Clomipramine | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Moderate | 1 | [
[
[
13,
24,
1237
]
],
[
[
13,
24,
684
],
[
684,
1,
1237
]
],
[
[
13,
63,
902
],
[
902,
40,
1237
]
],
[
[
13,
40,
114
],
[
114,
40,
... | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thioridazine"
... | Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Thioridazine and Thioridazine (Compound) resembles Clomipramine (Compound)
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam (Compound) resembles Clomipramine... |
DB00361 | DB08889 | 134 | 350 | [
"DDInter1939",
"DDInter299"
] | Vinorelbine | Carfilzomib | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combi... | Moderate | 1 | [
[
[
134,
24,
350
]
],
[
[
134,
18,
5795
],
[
5795,
45,
350
]
],
[
[
134,
6,
4973
],
[
4973,
45,
350
]
],
[
[
134,
21,
28762
],
[
28762,
... | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
]
],
[
[
"Vinorelbine",
"{u} (Compound) downregulates {v} (Gene)",
"PSMB8"
],
[
"PSMB8",
"{u} (Gene) is bound by {v} (Co... | Vinorelbine (Compound) downregulates PSMB8 (Gene) and PSMB8 (Gene) is bound by Carfilzomib (Compound)
Vinorelbine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Carfilzomib (Compound)
Vinorelbine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Carfilzomib (Compound)
Vinorelb... |
DB00631 | DB05294 | 372 | 1,069 | [
"DDInter405",
"DDInter1917"
] | Clofarabine | Vandetanib | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Moderate | 1 | [
[
[
372,
24,
1069
]
],
[
[
372,
63,
1195
],
[
1195,
40,
1069
]
],
[
[
372,
6,
17404
],
[
17404,
45,
1069
]
],
[
[
372,
21,
29343
],
[
2934... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vandetanib"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erlotinib"
],
[
... | Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Erlotinib and Erlotinib (Compound) resembles Vandetanib (Compound)
Clofarabine (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Vandetanib (Compound)
Clofarabine (Compound) causes Blood creatinine increased (Side Effec... |
DB00532 | DB11186 | 208 | 1,609 | [
"DDInter1152",
"DDInter1427"
] | Mephenytoin | Pentoxyverine | Mephenytoin is used for the treatment of refractory partial epilepsy. Mephenytoin is a solid. This compound belongs to the phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subuni... | Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant , and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists . Pentoxyverine acts on sigma... | Moderate | 1 | [
[
[
208,
24,
1609
]
],
[
[
208,
24,
649
],
[
649,
24,
1609
]
],
[
[
208,
63,
506
],
[
506,
24,
1609
]
],
[
[
208,
24,
649
],
[
649,
... | [
[
[
"Mephenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Mephenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
... | Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan... |
DB00402 | DB04868 | 1,407 | 478 | [
"DDInter685",
"DDInter1293"
] | Eszopiclone | Nilotinib | Eszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic drug used to treat insomnia. It is the active stereoisomer of zopiclone, belonging to the class of drugs known as _cyclopyrrolones_.[A179638,L6850] Cyclopyrrolone drugs demonstrate high efficacy and low toxicity, offering a ... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Moderate | 1 | [
[
[
1407,
24,
478
]
],
[
[
1407,
6,
6017
],
[
6017,
45,
478
]
],
[
[
1407,
21,
28963
],
[
28963,
60,
478
]
],
[
[
1407,
24,
1040
],
[
1040... | [
[
[
"Eszopiclone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Eszopiclone",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)"... | Eszopiclone (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilotinib (Compound)
Eszopiclone (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Nilotinib (Compound)
Eszopiclone may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafe... |
DB00398 | DB00679 | 79 | 684 | [
"DDInter1702",
"DDInter1796"
] | Sorafenib | Thioridazine | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | Major | 2 | [
[
[
79,
25,
684
]
],
[
[
79,
24,
1237
],
[
1237,
40,
684
]
],
[
[
79,
24,
216
],
[
216,
1,
684
]
],
[
[
79,
6,
12523
],
[
12523,
45,... | [
[
[
"Sorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thioridazine"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
],
[
"Clomipra... | Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine and Clomipramine (Compound) resembles Thioridazine (Compound)
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine and Chlorpromazine (Compound) resembles Thioridazi... |
DB00222 | DB01432 | 245 | 857 | [
"DDInter825",
"DDInter368"
] | Glimepiride | Cholestyramine | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Cholestyramine or colestyramine is a bile acid sequestrant. Bile acid sequestrants are polymeric compounds which serve as ion exchange resins. Cholestyramine resin is quite hydrophilic, but insoluble in water. | Moderate | 1 | [
[
[
245,
24,
857
]
],
[
[
245,
24,
1512
],
[
1512,
23,
857
]
],
[
[
245,
40,
1411
],
[
1411,
24,
857
]
],
[
[
245,
24,
870
],
[
870,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cholestyramine"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a minor interaction that can limit clinical effects when taken with Cholestyramine
Glimepiride (Compound) resembles Tolbutamide (Compound) and Tolbutamide may cause a moderate interaction that... |
DB01097 | DB09278 | 1,377 | 852 | [
"DDInter1033",
"DDInter24"
] | Leflunomide | Activated charcoal | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Activated charcoal, or activated carbon, is an amorphous form of carbon prepared from incomplete combustion of carbonaceous organic matter. It is activated by an oxidizing gas flow at high temperature passed over its surface to make a fine network of pores, producing a material with large surface area and high affinity... | Moderate | 1 | [
[
[
1377,
24,
852
]
],
[
[
1377,
24,
1411
],
[
1411,
24,
852
]
],
[
[
1377,
64,
1647
],
[
1647,
24,
852
]
],
[
[
1377,
25,
972
],
[
972,
... | [
[
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Activated charcoal"
]
],
[
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
... | Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Activated charcoal
Leflunomide may lead to a major life threatening interaction when taken with Acarbose and Acarbose ma... |
DB00364 | DB00365 | 417 | 839 | [
"DDInter1717",
"DDInter842"
] | Sucralfate | Grepafloxacin | Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia. It is considered a _cytoprotective agent_, protect... | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Moderate | 1 | [
[
[
417,
24,
839
]
],
[
[
417,
24,
1385
],
[
1385,
63,
839
]
],
[
[
417,
62,
1031
],
[
1031,
24,
839
]
],
[
[
417,
63,
1645
],
[
1645,
... | [
[
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Grepafloxacin"
]
],
[
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
],
... | Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide and Semaglutide may cause a moderate interaction that could exacerbate diseases when taken with Grepafloxacin
Sucralfate may cause a minor interaction that can limit clinical effects when taken with Theophylline and T... |
DB01036 | DB08865 | 211 | 1,593 | [
"DDInter1832",
"DDInter448"
] | Tolterodine | Crizotinib | Tolterodine is an antimuscarinic drug that is used to treat urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors. | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Moderate | 1 | [
[
[
211,
24,
1593
]
],
[
[
211,
6,
8374
],
[
8374,
45,
1593
]
],
[
[
211,
21,
29093
],
[
29093,
60,
1593
]
],
[
[
211,
24,
283
],
[
283,
... | [
[
[
"Tolterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Tolterodine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)... | Tolterodine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Tolterodine (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Crizotinib (Compound)
Tolterodine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedra... |
DB00881 | DB01131 | 954 | 1,243 | [
"DDInter1554",
"DDInter1531"
] | Quinapril | Proguanil | Quinapril is the ethyl ester prodrug of the non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat.[L8420,L8423] It is used to treat hypertension and heart failure.[L8420,L8423] ACE inhibitors are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta b... | Proguanil is a prophylactic antimalarial drug, which works by stopping the malaria parasite, _Plasmodium falciparum_ and _Plasmodium vivax_, from reproducing once it is in the red blood cells. It does this by inhibiting the enzyme, dihydrofolate reductase, which is involved in the reproduction of the parasite. | Moderate | 1 | [
[
[
954,
24,
1243
]
],
[
[
954,
21,
28658
],
[
28658,
60,
1243
]
],
[
[
954,
23,
1117
],
[
1117,
63,
1243
]
],
[
[
954,
21,
28658
],
[
286... | [
[
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Proguanil"
]
],
[
[
"Quinapril",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by... | Quinapril (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Proguanil (Compound)
Quinapril may cause a minor interaction that can limit clinical effects when taken with Sodium bicarbonate and Sodium bicarbonate may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB08820 | DB12147 | 1,478 | 241 | [
"DDInter997",
"DDInter661"
] | Ivacaftor | Erdafitinib | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations... | Moderate | 1 | [
[
[
1478,
24,
241
]
],
[
[
1478,
25,
1456
],
[
1456,
24,
241
]
],
[
[
1478,
24,
982
],
[
982,
63,
241
]
],
[
[
1478,
63,
1425
],
[
1425,
... | [
[
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erdafitinib"
]
],
[
[
"Ivacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
],
[
"Venetoclax"... | Ivacaftor may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib and Ivosidenib may cause a... |
DB00022 | DB00773 | 268 | 896 | [
"DDInter1408",
"DDInter702"
] | Peginterferon alfa-2b | Etoposide | Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Moderate | 1 | [
[
[
268,
24,
896
]
],
[
[
268,
24,
147
],
[
147,
23,
896
]
],
[
[
268,
24,
700
],
[
700,
63,
896
]
],
[
[
268,
25,
1477
],
[
1477,
6... | [
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinbla... | Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a minor interaction that can limit clinical effects when taken with Etoposide
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00853 | DB11988 | 1,686 | 270 | [
"DDInter1762",
"DDInter1321"
] | Temozolomide | Ocrelizumab | Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alky... | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-human... | Moderate | 1 | [
[
[
1686,
24,
270
]
],
[
[
1686,
63,
1461
],
[
1461,
23,
270
]
],
[
[
1686,
63,
134
],
[
134,
24,
270
]
],
[
[
1686,
24,
713
],
[
713,
... | [
[
[
"Temozolomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Temozolomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
... | Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab
Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vino... |
DB01044 | DB12245 | 246 | 823 | [
"DDInter809",
"DDInter1863"
] | Gatifloxacin | Triclabendazole | Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatiflox... | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common li... | Major | 2 | [
[
[
246,
25,
823
]
],
[
[
246,
62,
112
],
[
112,
23,
823
]
],
[
[
246,
64,
1010
],
[
1010,
24,
823
]
],
[
[
246,
24,
28
],
[
28,
24,... | [
[
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
]
],
[
[
"Gatifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"... | Gatifloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Gatifloxacin may lead to a major life threatening interaction when taken with Mefloquine and Mefloquine... |
DB00358 | DB06595 | 1,010 | 1,491 | [
"DDInter1140",
"DDInter1214"
] | Mefloquine | Midostaurin | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Moderate | 1 | [
[
[
1010,
24,
1491
]
],
[
[
1010,
23,
112
],
[
112,
23,
1491
]
],
[
[
1010,
24,
888
],
[
888,
24,
1491
]
],
[
[
1010,
24,
1017
],
[
1017,
... | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Mefloquine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Mefloquine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamo... |
DB00193 | DB12245 | 534 | 823 | [
"DDInter1841",
"DDInter1863"
] | Tramadol | Triclabendazole | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatmen... | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common li... | Moderate | 1 | [
[
[
534,
24,
823
]
],
[
[
534,
23,
112
],
[
112,
23,
823
]
],
[
[
534,
25,
1010
],
[
1010,
24,
823
]
],
[
[
534,
24,
28
],
[
28,
24,... | [
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Tramadol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Tramadol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Tramadol may lead to a major life threatening interaction when taken with Mefloquine and Mefloquine may cau... |
DB00188 | DB00222 | 168 | 245 | [
"DDInter222",
"DDInter825"
] | Bortezomib | Glimepiride | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Moderate | 1 | [
[
[
168,
24,
245
]
],
[
[
168,
24,
959
],
[
959,
1,
245
]
],
[
[
168,
6,
6017
],
[
6017,
45,
245
]
],
[
[
168,
21,
29007
],
[
29007,
... | [
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Glimepiride (Compound)
Bortezomib (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Glimepiride (Compound)
Bortezomib (Compound) causes Inappropriate antidiuretic hormone se... |
DB00682 | DB00888 | 126 | 1,001 | [
"DDInter1951",
"DDInter1133"
] | Warfarin | Mechlorethamine | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | A vesicant and necrotizing irritant destructive to mucous membranes, mechlorethamine is an alkylating drug. It was formerly used as a war gas. The hydrochloride is used as an antineoplastic in Hodgkin's disease and lymphomas. It causes severe gastrointestinal and bone marrow damage. The FDA granted marketing approval f... | Minor | 0 | [
[
[
126,
23,
1001
]
],
[
[
126,
63,
450
],
[
450,
1,
1001
]
],
[
[
126,
25,
646
],
[
646,
23,
1001
]
],
[
[
126,
64,
839
],
[
839,
2... | [
[
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mechlorethamine"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclophosphamide"
],
... | Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Cyclophosphamide and Cyclophosphamide (Compound) resembles Mechlorethamine (Compound)
Warfarin may lead to a major life threatening interaction when taken with Cinoxacin and Cinoxacin may cause a minor interaction that can limit cl... |
DB01168 | DB06674 | 1,053 | 908 | [
"DDInter1526",
"DDInter837"
] | Procarbazine | Golimumab | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Major | 2 | [
[
[
1053,
25,
908
]
],
[
[
1053,
63,
1461
],
[
1461,
23,
908
]
],
[
[
1053,
63,
336
],
[
336,
24,
908
]
],
[
[
1053,
24,
697
],
[
697,
... | [
[
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
]
],
[
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin ... | Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Golimumab
Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedip... |
DB09146 | DB14491 | 489 | 428 | [
"DDInter978",
"DDInter725"
] | Iron sucrose | Ferrous fumarate | Iron sucrose (sucroferric oxyhydroxide or iron saccharate) is used as a source of iron in patients with iron deficiency anemia with chronic kidney disease (CKD), including those who are undergoing dialysis (hemodialysis or peritoneal) and those who do not require dialysis. Due to less side effects than iron dextran, ir... | Used in treatment of iron deficiency anemia. | Moderate | 1 | [
[
[
489,
24,
428
]
],
[
[
489,
63,
1008
],
[
1008,
24,
428
]
],
[
[
489,
24,
821
],
[
821,
63,
428
]
],
[
[
489,
24,
933
],
[
933,
2... | [
[
[
"Iron sucrose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
]
],
[
[
"Iron sucrose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risedronic acid"
... | Iron sucrose may cause a moderate interaction that could exacerbate diseases when taken with Risedronic acid and Risedronic acid may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate
Iron sucrose may cause a moderate interaction that could exacerbate diseases when taken with G... |
DB06791 | DB09038 | 1,446 | 1,450 | [
"DDInter1021",
"DDInter636"
] | Lanreotide | Empagliflozin | Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured ... | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
1446,
24,
1450
]
],
[
[
1446,
63,
461
],
[
461,
24,
1450
]
],
[
[
1446,
24,
1017
],
[
1017,
63,
1450
]
],
[
[
1446,
64,
171
],
[
171,
... | [
[
[
"Lanreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Lanreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
],
[
... | Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatini... |
DB12332 | DB15091 | 1,619 | 676 | [
"DDInter1626",
"DDInter1901"
] | Rucaparib | Upadacitinib | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
1619,
25,
676
]
],
[
[
1619,
63,
1430
],
[
1430,
24,
676
]
],
[
[
1619,
24,
283
],
[
283,
24,
676
]
],
[
[
1619,
64,
1593
],
[
1593,
... | [
[
[
"Rucaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
"Sipuleuc... | Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fe... |
DB01211 | DB14761 | 609 | 242 | [
"DDInter393",
"DDInter1578"
] | Clarithromycin | Remdesivir | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends o... | Moderate | 1 | [
[
[
609,
24,
242
]
],
[
[
609,
63,
1130
],
[
1130,
24,
242
]
],
[
[
609,
64,
467
],
[
467,
24,
242
]
],
[
[
609,
24,
129
],
[
129,
2... | [
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
]... | Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone and Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Clarithromycin may lead to a major life threatening interaction when taken with Simvastatin and Simvasta... |
DB00444 | DB00564 | 63 | 1,236 | [
"DDInter1765",
"DDInter293"
] | Teniposide | Carbamazepine | Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells ... | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbam... | Moderate | 1 | [
[
[
63,
24,
1236
]
],
[
[
63,
23,
307
],
[
307,
1,
1236
]
],
[
[
63,
63,
362
],
[
362,
1,
1236
]
],
[
[
63,
24,
1335
],
[
1335,
40,
... | [
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbamazepine"
]
],
[
[
"Teniposide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
... | Teniposide may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil (Compound) resembles Carbamazepine (Compound)
Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Carbamazepine (Compound)
... |
DB06791 | DB13928 | 1,446 | 1,385 | [
"DDInter1021",
"DDInter1660"
] | Lanreotide | Semaglutide | Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analog of the drug somatostatin, a growth hormone inhibitor. Lanreotide is manufactured ... | Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved ... | Moderate | 1 | [
[
[
1446,
24,
1385
]
],
[
[
1446,
24,
154
],
[
154,
24,
1385
]
],
[
[
1446,
63,
1144
],
[
1144,
24,
1385
]
],
[
[
1446,
24,
154
],
[
154,
... | [
[
[
"Lanreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Lanreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
],
[
... | Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone and Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Lanreotide may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nate... |
DB00880 | DB00902 | 359 | 104 | [
"DDInter360",
"DDInter1168"
] | Chlorothiazide | Methdilazine | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812) | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Moderate | 1 | [
[
[
359,
24,
104
]
],
[
[
359,
24,
820
],
[
820,
1,
104
]
],
[
[
359,
24,
401
],
[
401,
63,
104
]
],
[
[
359,
24,
286
],
[
286,
62,
... | [
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Chlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
... | Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine (Compound) resembles Methdilazine (Compound)
Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate intera... |
DB00207 | DB12332 | 1,570 | 1,619 | [
"DDInter157",
"DDInter1626"
] | Azithromycin | Rucaparib | Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration. It was initially approved by the FDA in 1991. It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually tra... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
1570,
24,
1619
]
],
[
[
1570,
23,
112
],
[
112,
23,
1619
]
],
[
[
1570,
24,
1662
],
[
1662,
24,
1619
]
],
[
[
1570,
25,
1250
],
[
1250... | [
[
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Azithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Azithromycin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric aci... |
DB00777 | DB00836 | 146 | 543 | [
"DDInter1537",
"DDInter1088"
] | Propiomazine | Loperamide | Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Struct... | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | Moderate | 1 | [
[
[
146,
24,
543
]
],
[
[
146,
1,
11392
],
[
11392,
40,
543
]
],
[
[
146,
63,
262
],
[
262,
24,
543
]
],
[
[
146,
64,
475
],
[
475,
... | [
[
[
"Propiomazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
]
],
[
[
"Propiomazine",
"{u} (Compound) resembles {v} (Compound)",
"Methadyl Acetate"
],
[
"Methadyl Acetate",
"{u} (Co... | Propiomazine (Compound) resembles Methadyl Acetate (Compound) and Methadyl Acetate (Compound) resembles Loperamide (Compound)
Propiomazine may cause a moderate interaction that could exacerbate diseases when taken with Clidinium and Clidinium may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB12141 | DB14881 | 971 | 180 | [
"DDInter817",
"DDInter1329"
] | Gilteritinib | Oliceridine | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Moderate | 1 | [
[
[
971,
24,
180
]
],
[
[
971,
62,
112
],
[
112,
23,
180
]
],
[
[
971,
63,
401
],
[
401,
24,
180
]
],
[
[
971,
24,
1476
],
[
1476,
2... | [
[
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Gilteritinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Gilteritinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Oliceridine
Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Promethazine a... |
DB08903 | DB12332 | 996 | 1,619 | [
"DDInter170",
"DDInter1626"
] | Bedaquiline | Rucaparib | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affe... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Major | 2 | [
[
[
996,
25,
1619
]
],
[
[
996,
62,
112
],
[
112,
23,
1619
]
],
[
[
996,
25,
1662
],
[
1662,
24,
1619
]
],
[
[
996,
63,
1419
],
[
1419,
... | [
[
[
"Bedaquiline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
]
],
[
[
"Bedaquiline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronid... | Bedaquiline may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Bedaquiline may lead to a major life threatening interaction when taken with Picosulfuric acid and Picosulfuri... |
DB00581 | DB11796 | 355 | 1,612 | [
"DDInter1018",
"DDInter786"
] | Lactulose | Fostemsavir | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its p... | Fostemsavir is the phosphonooxymethyl prodrug of temsavir, a novel HIV-1 attachment inhibitor. It binds to and inhibits the activity of gp120, a subunit within the HIV-1 gp160 envelope glycoprotein that facilitates the attachment of HIV-1 to host cell CD4 receptors - in doing so, temsavir prevents the first step in the... | Moderate | 1 | [
[
[
355,
24,
1612
]
],
[
[
355,
24,
1220
],
[
1220,
23,
1612
]
],
[
[
355,
63,
1424
],
[
1424,
24,
1612
]
],
[
[
355,
24,
823
],
[
823,
... | [
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
]
],
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
... | Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Fostemsavir
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinin... |
DB00556 | DB13074 | 1,262 | 877 | [
"DDInter1429",
"DDInter1110"
] | Perflutren | Macimorelin | Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultras... | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Moderate | 1 | [
[
[
1262,
24,
877
]
],
[
[
1262,
23,
112
],
[
112,
23,
877
]
],
[
[
1262,
24,
913
],
[
913,
24,
877
]
],
[
[
1262,
24,
485
],
[
485,
... | [
[
[
"Perflutren",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Perflutren",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Perflutren may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Perflutren may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Ap... |
DB00911 | DB01095 | 458 | 671 | [
"DDInter1811",
"DDInter769"
] | Tinidazole | Fluvastatin | A nitroimidazole antitrichomonal agent effective against _Trichomonas vaginalis_, _Entamoeba histolytica_, and _Giardia lamblia_ infections. | Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Fluvastatin belongs to a class of medications called statins and is used to r... | Moderate | 1 | [
[
[
458,
24,
671
]
],
[
[
458,
24,
788
],
[
788,
40,
671
]
],
[
[
458,
24,
14
],
[
14,
63,
671
]
],
[
[
458,
6,
8374
],
[
8374,
45,
... | [
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
]
],
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
],
[... | Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin (Compound) resembles Fluvastatin (Compound)
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction t... |
DB06688 | DB13985 | 1,430 | 546 | [
"DDInter1677",
"DDInter1108"
] | Sipuleucel-T | Lutetium Lu 177 dotatate | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared sp... | A 177Lu-labeled somatostatin analog peptide, Lutetium Lu 177 dotatate belongs to an emerging form of treatments called Peptide Receptor Radionuclide Therapy (PRRT), which involves targeting tumours with molecules carrying radioactive particles that bind to specific receptors expressed by the tumour. Lutetium Lu 177 dot... | Moderate | 1 | [
[
[
1430,
24,
546
]
],
[
[
1430,
63,
66
],
[
66,
24,
546
]
],
[
[
1430,
24,
270
],
[
270,
24,
546
]
],
[
[
1430,
63,
1057
],
[
1057,
... | [
[
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lutetium Lu 177 dotatate"
]
],
[
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizuma... | Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Lutetium Lu 177 dotatate
Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Ocr... |
DB00765 | DB01501 | 1,266 | 1,118 | [
"DDInter1205",
"DDInter549"
] | Metyrosine | Difenoxin | An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma. (Martindale, The Extra Pharmacopoeia, 30th ed) | Difenoxin is a 4-phenylpiperidine which is closely related to the opioid analgesic meperidine. Difenoxin alone is a USA Schedule I controlled drug, as it may be habit forming. However, it is listed as a Schedule IV controlled drug if combined with atropine, which is added to decrease deliberate misuse. Motofen(R) is a ... | Moderate | 1 | [
[
[
1266,
24,
1118
]
],
[
[
1266,
24,
1688
],
[
1688,
40,
1118
]
],
[
[
1266,
63,
506
],
[
506,
24,
1118
]
],
[
[
1266,
24,
1609
],
[
1609... | [
[
[
"Metyrosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Difenoxin"
]
],
[
[
"Metyrosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenoxylate"
],
[
... | Metyrosine may cause a moderate interaction that could exacerbate diseases when taken with Diphenoxylate and Diphenoxylate (Compound) resembles Difenoxin (Compound)
Metyrosine may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate inter... |
DB08908 | DB12674 | 713 | 975 | [
"DDInter564",
"DDInter1105"
] | Dimethyl fumarate | Lurbinectedin | Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis.[A253942,L43752] The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MM... | Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma, chronic lymphocytic leukemia (CLL), breast cancer, and small-cell lung cancer (SCLC). It is a derivative of the marine-derived agent ecteinascidin ([trabectedin]), an anticancer agent fou... | Moderate | 1 | [
[
[
713,
24,
975
]
],
[
[
713,
63,
1488
],
[
1488,
24,
975
]
],
[
[
713,
24,
1613
],
[
1613,
24,
975
]
],
[
[
713,
24,
994
],
[
994,
... | [
[
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurbinectedin"
]
],
[
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabin... | Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Pe... |
DB00418 | DB00877 | 536 | 629 | [
"DDInter1650",
"DDInter1678"
] | Secobarbital | Sirolimus | Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom. | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Moderate | 1 | [
[
[
536,
24,
629
]
],
[
[
536,
21,
28898
],
[
28898,
60,
629
]
],
[
[
536,
24,
1476
],
[
1476,
63,
629
]
],
[
[
536,
24,
167
],
[
167,
... | [
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Secobarbital",
"{u} (Compound) causes {v} (Side Effect)",
"Constipation"
],
[
"Constipation",
"{u} (Side Effect... | Secobarbital (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Sirolimus (Compound)
Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB01087 | DB05316 | 1,520 | 749 | [
"DDInter1520",
"DDInter1467"
] | Primaquine | Pimavanserin | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT<sub>2A</sub> and HT<sub>2C</sub> receptors. Unlike other atypical antipsychotic... | Moderate | 1 | [
[
[
1520,
24,
749
]
],
[
[
1520,
62,
112
],
[
112,
23,
749
]
],
[
[
1520,
24,
1264
],
[
1264,
24,
749
]
],
[
[
1520,
63,
521
],
[
521,
... | [
[
[
"Primaquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pimavanserin"
]
],
[
[
"Primaquine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[... | Primaquine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pimavanserin
Primaquine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxep... |
DB00443 | DB09280 | 251 | 1,604 | [
"DDInter195",
"DDInter1101"
] | Betamethasone | Lumacaftor | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Moderate | 1 | [
[
[
251,
24,
1604
]
],
[
[
251,
24,
1171
],
[
1171,
24,
1604
]
],
[
[
251,
25,
593
],
[
593,
24,
1604
]
],
[
[
251,
1,
1573
],
[
1573,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meloxicam"
],
... | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Meloxicam and Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Betamethasone may lead to a major life threatening interaction when taken with Bupropion and Bupropion may caus... |
DB00477 | DB00681 | 216 | 1,287 | [
"DDInter363",
"DDInter85"
] | Chlorpromazine | Amphotericin B | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphot... | Moderate | 1 | [
[
[
216,
24,
1287
]
],
[
[
216,
21,
28671
],
[
28671,
60,
1287
]
],
[
[
216,
63,
600
],
[
600,
23,
1287
]
],
[
[
216,
24,
1532
],
[
1532,
... | [
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphotericin B"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) causes {v} (Side Effect)",
"Dysphagia"
],
[
"Dysphagia",
"{u} (Side Eff... | Chlorpromazine (Compound) causes Dysphagia (Side Effect) and Dysphagia (Side Effect) is caused by Amphotericin B (Compound)
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken ... |
DB00196 | DB01236 | 600 | 679 | [
"DDInter743",
"DDInter1664"
] | Fluconazole | Sevoflurane | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient. Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 199... | Moderate | 1 | [
[
[
600,
24,
679
]
],
[
[
600,
24,
1262
],
[
1262,
40,
679
]
],
[
[
600,
6,
8374
],
[
8374,
45,
679
]
],
[
[
600,
21,
28751
],
[
28751,
... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sevoflurane"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perflutren"
],
[... | Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Perflutren and Perflutren (Compound) resembles Sevoflurane (Compound)
Fluconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sevoflurane (Compound)
Fluconazole (Compound) causes Convulsion (Side Effect) and Con... |
DB00440 | DB01229 | 1,548 | 973 | [
"DDInter1874",
"DDInter1377"
] | Trimethoprim | Paclitaxel | Trimethoprim is an antifolate antibacterial agent that inhibits bacterial dihydrofolate reductase (DHFR), a critical enzyme that catalyzes the formation of tetrahydrofolic acid (THF) - in doing so, it prevents the synthesis of bacterial DNA and ultimately continued bacterial survival. Trimethoprim is often used in comb... | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Moderate | 1 | [
[
[
1548,
24,
973
]
],
[
[
1548,
6,
8374
],
[
8374,
45,
973
]
],
[
[
1548,
6,
8569
],
[
8569,
57,
973
]
],
[
[
1548,
21,
29501
],
[
29501,... | [
[
[
"Trimethoprim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Trimethoprim",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Trimethoprim (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Paclitaxel (Compound)
Trimethoprim (Compound) binds TYMS (Gene) and TYMS (Gene) is downregulated by Paclitaxel (Compound)
Trimethoprim (Compound) causes Hepatic necrosis (Side Effect) and Hepatic necrosis (Side Effect) is caused by Paclitaxel (Co... |
DB00446 | DB00456 | 597 | 164 | [
"DDInter351",
"DDInter311"
] | Chloramphenicol | Cefalotin | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Cefalotin is a cephalosporin antibiotic. | Moderate | 1 | [
[
[
597,
24,
164
]
],
[
[
597,
24,
1087
],
[
1087,
1,
164
]
],
[
[
597,
63,
149
],
[
149,
1,
164
]
],
[
[
597,
6,
10612
],
[
10612,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefalotin"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefotaxime"
],... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Cefotaxime and Cefotaxime (Compound) resembles Cefalotin (Compound)
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Ceftazidime and Ceftazidime (Compound) resembles Cefalotin (... |
DB06372 | DB15091 | 259 | 676 | [
"DDInter1594",
"DDInter1901"
] | Rilonacept | Upadacitinib | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold au... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
259,
25,
676
]
],
[
[
259,
23,
1193
],
[
1193,
23,
676
]
],
[
[
259,
62,
1461
],
[
1461,
23,
676
]
],
[
[
259,
24,
1430
],
[
1430,
... | [
[
[
"Rilonacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Rilonacept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc g... | Rilonacept may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Upadacitinib
Rilonacept may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vit... |
DB00286 | DB01234 | 380 | 1,220 | [
"DDInter439",
"DDInter513"
] | Conjugated estrogens | Dexamethasone | The conjugated estrogens are noncrystalline mixtures of purified female sex hormones obtained either by its isolation from the urine of pregnant mares or by synthetic generation from vegetal material. Both of these products are later conjugated to natrium sulfate by ester bonds in order to make them more water soluble.... | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Moderate | 1 | [
[
[
380,
24,
1220
]
],
[
[
380,
24,
870
],
[
870,
1,
1220
]
],
[
[
380,
24,
175
],
[
175,
40,
1220
]
],
[
[
380,
6,
6648
],
[
6648,
... | [
[
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flud... | Conjugated estrogens may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Conjugated estrogens may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Com... |
DB00674 | DB01069 | 1,516 | 401 | [
"DDInter802",
"DDInter1533"
] | Galantamine | Promethazine | Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sour... | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
1516,
24,
401
]
],
[
[
1516,
24,
1264
],
[
1264,
63,
401
]
],
[
[
1516,
24,
104
],
[
104,
24,
401
]
],
[
[
1516,
6,
12523
],
[
12523,
... | [
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdi... |
DB00434 | DB08815 | 13 | 154 | [
"DDInter459",
"DDInter1104"
] | Cyproheptadine | Lurasidone | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. | Moderate | 1 | [
[
[
13,
24,
154
]
],
[
[
13,
6,
2250
],
[
2250,
45,
154
]
],
[
[
13,
21,
29118
],
[
29118,
60,
154
]
],
[
[
13,
24,
1532
],
[
1532,
... | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
]
],
[
[
"Cyproheptadine",
"{u} (Compound) binds {v} (Gene)",
"DRD2"
],
[
"DRD2",
"{u} (Gene) is bound by {v} (Compoun... | Cyproheptadine (Compound) binds DRD2 (Gene) and DRD2 (Gene) is bound by Lurasidone (Compound)
Cyproheptadine (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Lurasidone (Compound)
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfam... |
DB00783 | DB01110 | 1,438 | 86 | [
"DDInter679",
"DDInter1209"
] | Estradiol | Miconazole | Estradiol is a naturally occurring hormone circulating endogenously in females. It is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen, such as vulvovaginal atrophy and hot flashes. Some available forms of estradiol include oral tablets, injections, vag... | Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-ba... | Moderate | 1 | [
[
[
1438,
24,
86
]
],
[
[
1438,
6,
10215
],
[
10215,
45,
86
]
],
[
[
1438,
18,
10375
],
[
10375,
57,
86
]
],
[
[
1438,
21,
29122
],
[
2912... | [
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miconazole"
]
],
[
[
"Estradiol",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",... | Estradiol (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Miconazole (Compound)
Estradiol (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Miconazole (Compound)
Estradiol (Compound) causes Mediastinal disorder (Side Effect) and Mediastinal disorder (Side Effect) is caused by M... |
DB00048 | DB12364 | 1,595 | 1,421 | [
"DDInter435",
"DDInter200"
] | Collagenase clostridium histolyticum | Betrixaban | Collagenase clostridium histolyticum is an enzyme produced by the bacterium Clostridium histolyticum. It is beneficial in the breakdown of collagen plaques for the treatment of Dupuytren's contracture and Peyronie's disease. The topical formulation is used for the debridement of necrotic tissue due to burns or chronic ... | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals ... | Moderate | 1 | [
[
[
1595,
24,
1421
]
],
[
[
1595,
24,
714
],
[
714,
25,
1421
]
],
[
[
1595,
63,
582
],
[
582,
25,
1421
]
],
[
[
1595,
24,
714
],
[
714,
... | [
[
[
"Collagenase clostridium histolyticum",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Collagenase clostridium histolyticum",
"{u} may cause a moderate interaction that could exacerbate diseases when... | Collagenase clostridium histolyticum may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may lead to a major life threatening interaction when taken with Betrixaban
Collagenase clostridium histolyticum may cause a moderate interaction that could exacerbate diseases when... |
DB00635 | DB00731 | 1,573 | 1,144 | [
"DDInter1515",
"DDInter1269"
] | Prednisone | Nateglinide | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Moderate | 1 | [
[
[
1573,
24,
1144
]
],
[
[
1573,
63,
610
],
[
610,
24,
1144
]
],
[
[
1573,
6,
1829
],
[
1829,
45,
1144
]
],
[
[
1573,
21,
28787
],
[
2878... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enalapril"
],
[
... | Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Enalapril and Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Prednisone (Compound) binds ALB (Gene) and ALB (Gene) is bound by Nateglinide (Compound)
Prednisone (Compound) ca... |
DB00439 | DB12130 | 289 | 1,017 | [
"DDInter341",
"DDInter1094"
] | Cerivastatin | Lorlatinib | On August 8, 2001 the U.S. Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal rhabdomyolysis, a severe adverse reaction from this cholesterol-lowering (lipid-lowering) product. It has also been withdrawn from the Cana... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
289,
24,
1017
]
],
[
[
289,
24,
14
],
[
14,
24,
1017
]
],
[
[
289,
63,
134
],
[
134,
24,
1017
]
],
[
[
289,
24,
159
],
[
159,
63... | [
[
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
],
... | Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine a... |
DB00621 | DB05528 | 1,026 | 1,070 | [
"DDInter1357",
"DDInter1228"
] | Oxandrolone | Mipomersen | A synthetic hormone with anabolic and androgenic properties. | Mipomersen sodium, which was known as the investigational drug, isis-301012, is the salt form of a synthetic phosphorothioate oligonucleotide. Mipomersen sodium prevents the formation of apo B-100, resulting in a decrease in the levels of apolipoprotein B (apo B), low density lipoprotein (LDL), and total cholesterol. M... | Major | 2 | [
[
[
1026,
25,
1070
]
],
[
[
1026,
40,
1687
],
[
1687,
64,
1070
]
],
[
[
1026,
63,
1512
],
[
1512,
25,
1070
]
],
[
[
1026,
25,
350
],
[
350... | [
[
[
"Oxandrolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mipomersen"
]
],
[
[
"Oxandrolone",
"{u} (Compound) resembles {v} (Compound)",
"Stanozolol"
],
[
"Stanozolol",
"{u} may lead to a major life threate... | Oxandrolone (Compound) resembles Stanozolol (Compound) and Stanozolol may lead to a major life threatening interaction when taken with Mipomersen
Oxandrolone may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may lead to a major life threatening interaction when ta... |
DB00986 | DB01409 | 1,192 | 1,415 | [
"DDInter834",
"DDInter1815"
] | Glycopyrronium | Tiotropium | Glycopyrronium, also known as NVA237 or glycopyrrolate, is a racemic mixture of two enantiomers. They are both quaternary ammonium compounds and long acting muscarinic antagonists. It is one of the most commonly prescribed anticholinergic medications.[A233535,A233540] Early research into glycopyrronium use was for its ... | Tiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma.[A180163,L7084,L7087,L7090,L7093] Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.[A180163,L7084,L... | Moderate | 1 | [
[
[
1192,
24,
1415
]
],
[
[
1192,
6,
4304
],
[
4304,
45,
1415
]
],
[
[
1192,
21,
29187
],
[
29187,
60,
1415
]
],
[
[
1192,
63,
146
],
[
14... | [
[
[
"Glycopyrronium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tiotropium"
]
],
[
[
"Glycopyrronium",
"{u} (Compound) binds {v} (Gene)",
"CHRM2"
],
[
"CHRM2",
"{u} (Gene) is bound by {v} (Compo... | Glycopyrronium (Compound) binds CHRM2 (Gene) and CHRM2 (Gene) is bound by Tiotropium (Compound)
Glycopyrronium (Compound) causes Rhinitis (Side Effect) and Rhinitis (Side Effect) is caused by Tiotropium (Compound)
Glycopyrronium may cause a moderate interaction that could exacerbate diseases when taken with Propiomazin... |
DB00241 | DB05239 | 288 | 866 | [
"DDInter257",
"DDInter425"
] | Butalbital | Cobimetinib | Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervou... | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment ... | Moderate | 1 | [
[
[
288,
24,
866
]
],
[
[
288,
24,
214
],
[
214,
63,
866
]
],
[
[
288,
24,
888
],
[
888,
24,
866
]
],
[
[
288,
40,
1023
],
[
1023,
2... | [
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobimetinib"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[... | Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Cobimetinib
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Ta... |
DB01131 | DB12500 | 1,243 | 283 | [
"DDInter1531",
"DDInter714"
] | Proguanil | Fedratinib | Proguanil is a prophylactic antimalarial drug, which works by stopping the malaria parasite, _Plasmodium falciparum_ and _Plasmodium vivax_, from reproducing once it is in the red blood cells. It does this by inhibiting the enzyme, dihydrofolate reductase, which is involved in the reproduction of the parasite. | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
1243,
24,
283
]
],
[
[
1243,
24,
436
],
[
436,
24,
283
]
],
[
[
1243,
63,
535
],
[
535,
24,
283
]
],
[
[
1243,
63,
307
],
[
307,
... | [
[
[
"Proguanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Proguanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Artemether"
],
[
... | Proguanil may cause a moderate interaction that could exacerbate diseases when taken with Artemether and Artemether may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Proguanil may cause a moderate interaction that could exacerbate diseases when taken with Fenofibrate and Fenofib... |
DB00545 | DB11363 | 751 | 1,276 | [
"DDInter1548",
"DDInter39"
] | Pyridostigmine | Alectinib | Myasthenia gravis is an autoimmune disease involving dysfunction at the neuromuscular junction, most commonly due to autoantibodies directed against the acetylcholine receptor (AChR), which results in muscle tone loss, muscle weakness, and fatigue. Acetylcholinesterase inhibitors have been the symptomatic treatment of ... | Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes prol... | Moderate | 1 | [
[
[
751,
24,
1276
]
],
[
[
751,
24,
61
],
[
61,
24,
1276
]
],
[
[
751,
24,
1476
],
[
1476,
63,
1276
]
],
[
[
751,
40,
1372
],
[
1372,
... | [
[
[
"Pyridostigmine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alectinib"
]
],
[
[
"Pyridostigmine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edrophonium"
],
... | Pyridostigmine may cause a moderate interaction that could exacerbate diseases when taken with Edrophonium and Edrophonium may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Pyridostigmine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib a... |
DB00812 | DB06441 | 998 | 936 | [
"DDInter1451",
"DDInter283"
] | Phenylbutazone | Cangrelor | A drug that has anti-inflammatory, antipyretic, and analgesic activities. It is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication). Although phenylbutazone is effective in gouty arthritis, risk/benefit conside... | Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an act... | Moderate | 1 | [
[
[
998,
24,
936
]
],
[
[
998,
1,
97
],
[
97,
24,
936
]
],
[
[
998,
24,
477
],
[
477,
24,
936
]
],
[
[
998,
63,
305
],
[
305,
24,
... | [
[
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cangrelor"
]
],
[
[
"Phenylbutazone",
"{u} (Compound) resembles {v} (Compound)",
"Oxaprozin"
],
[
"Oxaprozin",
"{u} may cause a mo... | Phenylbutazone (Compound) resembles Oxaprozin (Compound) and Oxaprozin may cause a moderate interaction that could exacerbate diseases when taken with Cangrelor
Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may cause a moderate interaction that ... |
DB00749 | DB09156 | 59 | 777 | [
"DDInter699",
"DDInter964"
] | Etodolac | Iopromide | Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. | Iopromide is a low osmolar, non-ionic X-ray contrast agent for intravascular administration. It functions as a contrast agent by opacifying blood vessels in the flow path of the contrast agent, permitting radiographic visualization of the internal structures until significant hemodilution occurs. Although iopromide can... | Major | 2 | [
[
[
59,
25,
777
]
],
[
[
59,
63,
372
],
[
372,
25,
777
]
],
[
[
59,
24,
712
],
[
712,
25,
777
]
],
[
[
59,
64,
663
],
[
663,
25,
... | [
[
[
"Etodolac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iopromide"
]
],
[
[
"Etodolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
],
[
"Clofarabine",
... | Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may lead to a major life threatening interaction when taken with Iopromide
Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Olsalazine may lead to a... |
DB00963 | DB06605 | 1,263 | 1,409 | [
"DDInter241",
"DDInter108"
] | Bromfenac | Apixaban | Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation. Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool f... | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Major | 2 | [
[
[
1263,
25,
1409
]
],
[
[
1263,
21,
29122
],
[
29122,
60,
1409
]
],
[
[
1263,
63,
1560
],
[
1560,
24,
1409
]
],
[
[
1263,
24,
1220
],
[
... | [
[
[
"Bromfenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
],
[
[
"Bromfenac",
"{u} (Compound) causes {v} (Side Effect)",
"Mediastinal disorder"
],
[
"Mediastinal disorder",
"{u} (Side Effect) is c... | Bromfenac (Compound) causes Mediastinal disorder (Side Effect) and Mediastinal disorder (Side Effect) is caused by Apixaban (Compound)
Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases w... |
DB00400 | DB00468 | 353 | 1,424 | [
"DDInter843",
"DDInter1557"
] | Griseofulvin | Quinine | An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Moderate | 1 | [
[
[
353,
24,
1424
]
],
[
[
353,
6,
7950
],
[
7950,
45,
1424
]
],
[
[
353,
21,
28680
],
[
28680,
60,
1424
]
],
[
[
353,
24,
307
],
[
307,
... | [
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
]
],
[
[
"Griseofulvin",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)"... | Griseofulvin (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Quinine (Compound)
Griseofulvin (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Quinine (Compound)
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may c... |
DB00495 | DB06616 | 139 | 594 | [
"DDInter1961",
"DDInter224"
] | Zidovudine | Bosutinib | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain... | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Moderate | 1 | [
[
[
139,
24,
594
]
],
[
[
139,
6,
8374
],
[
8374,
45,
594
]
],
[
[
139,
21,
29231
],
[
29231,
60,
594
]
],
[
[
139,
24,
713
],
[
713,
... | [
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Zidovudine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Zidovudine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bosutinib (Compound)
Zidovudine (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Bosutinib (Compound)
Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Dimethy... |
DB00197 | DB01144 | 1,324 | 1,326 | [
"DDInter1881",
"DDInter540"
] | Troglitazone | Diclofenamide | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | A carbonic anhydrase inhibitor that is used in the treatment of glaucoma. | Moderate | 1 | [
[
[
1324,
24,
1326
]
],
[
[
1324,
24,
504
],
[
504,
1,
1326
]
],
[
[
1324,
24,
359
],
[
359,
40,
1326
]
],
[
[
1324,
24,
1019
],
[
1019,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenamide"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrochlorothiazide"... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Hydrochlorothiazide and Hydrochlorothiazide (Compound) resembles Diclofenamide (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide and Chlorothiazide (Compound)... |
DB00307 | DB08880 | 1,101 | 1,510 | [
"DDInter202",
"DDInter1771"
] | Bexarotene | Teriflunomide | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
1101,
25,
1510
]
],
[
[
1101,
62,
608
],
[
608,
23,
1510
]
],
[
[
1101,
24,
129
],
[
129,
63,
1510
]
],
[
[
1101,
23,
1612
],
[
1612,
... | [
[
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
"Lidocaine"... | Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Teriflunomide
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalut... |
DB00341 | DB11642 | 1,242 | 938 | [
"DDInter343",
"DDInter1480"
] | Cetirizine | Pitolisant | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allerg... | Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnag... | Moderate | 1 | [
[
[
1242,
24,
938
]
],
[
[
1242,
24,
1233
],
[
1233,
24,
938
]
],
[
[
1242,
40,
1413
],
[
1413,
24,
938
]
],
[
[
1242,
63,
475
],
[
475,
... | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triprolidine"
],
[
... | Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Triprolidine and Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Cetirizine (Compound) resembles Fexofenadine (Compound) and Fexofenadine may cause a moderate interaction th... |
DB00618 | DB01024 | 1,572 | 1,096 | [
"DDInter498",
"DDInter1252"
] | Demeclocycline | Mycophenolic acid | A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time. | Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a c... | Moderate | 1 | [
[
[
1572,
24,
1096
]
],
[
[
1572,
24,
955
],
[
955,
1,
1096
]
],
[
[
1572,
24,
1193
],
[
1193,
62,
1096
]
],
[
[
1572,
63,
1031
],
[
1031,... | [
[
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
]
],
[
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolat... | Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil and Mycophenolate mofetil (Compound) resembles Mycophenolic acid (Compound)
Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Zinc gluconate and Zinc gluconat... |
DB00635 | DB01080 | 1,573 | 855 | [
"DDInter1515",
"DDInter1933"
] | Prednisone | Vigabatrin | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Vigabatrin is an analog of gamma-aminobutyric acid ([GABA]), the main inhibitory neurotransmitter in the central nervous system, used in the treatment of refractory seizures and infantile spasms. It irreversibly inhibits the enzyme responsible for GABA metabolism, thereby increasing levels of circulating GABA. Although... | Major | 2 | [
[
[
1573,
25,
855
]
],
[
[
1573,
21,
28768
],
[
28768,
60,
855
]
],
[
[
1573,
25,
770
],
[
770,
24,
855
]
],
[
[
1573,
1,
617
],
[
617,
... | [
[
[
"Prednisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vigabatrin"
]
],
[
[
"Prednisone",
"{u} (Compound) causes {v} (Side Effect)",
"Acne"
],
[
"Acne",
"{u} (Side Effect) is caused by {v} (Compound)",
... | Prednisone (Compound) causes Acne (Side Effect) and Acne (Side Effect) is caused by Vigabatrin (Compound)
Prednisone may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Vigabatrin
Prednisone (Compoun... |
DB00619 | DB09054 | 1,419 | 384 | [
"DDInter909",
"DDInter905"
] | Imatinib | Idelalisib | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
1419,
24,
384
]
],
[
[
1419,
23,
222
],
[
222,
23,
384
]
],
[
[
1419,
62,
1230
],
[
1230,
23,
384
]
],
[
[
1419,
23,
1627
],
[
1627,
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Imatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
"... | Imatinib may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Imatinib may cause a minor interaction that can limit clinical effects when taken with Citalopram and Citalopram may... |
DB00960 | DB01069 | 887 | 401 | [
"DDInter1471",
"DDInter1533"
] | Pindolol | Promethazine | Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. Research into pindolol's use in the treatment of hypertension began in the earl... | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
887,
24,
401
]
],
[
[
887,
24,
1264
],
[
1264,
63,
401
]
],
[
[
887,
63,
104
],
[
104,
24,
401
]
],
[
[
887,
6,
12523
],
[
12523,
... | [
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"... | Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine... |
DB01162 | DB01285 | 195 | 708 | [
"DDInter1767",
"DDInter445"
] | Terazosin | Corticotropin | Terazosin is a quinazoline derivative alpha-1-selective adrenergic blocking agent indicated for benign prostatic hyperplasia and hypertension[FDA Label]. Terazosin blocks adrenaline's action on alpha-1 adrenergic receptors, causing relaxation of smooth muscle in blood vessels and the prostate. | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Moderate | 1 | [
[
[
195,
24,
708
]
],
[
[
195,
1,
1205
],
[
1205,
24,
708
]
],
[
[
195,
24,
1450
],
[
1450,
63,
708
]
],
[
[
195,
63,
1648
],
[
1648,
... | [
[
[
"Terazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Terazosin",
"{u} (Compound) resembles {v} (Compound)",
"Prazosin"
],
[
"Prazosin",
"{u} may cause a moderate i... | Terazosin (Compound) resembles Prazosin (Compound) and Prazosin may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Terazosin may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that co... |
DB09061 | DB09065 | 1,627 | 760 | [
"DDInter284",
"DDInter424"
] | Cannabidiol | Cobicistat | Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical i... | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Minor | 0 | [
[
[
1627,
23,
760
]
],
[
[
1627,
63,
1101
],
[
1101,
23,
760
]
],
[
[
1627,
63,
1195
],
[
1195,
24,
760
]
],
[
[
1627,
62,
723
],
[
723,
... | [
[
[
"Cannabidiol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cobicistat"
]
],
[
[
"Cannabidiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Erlotinib and Erlotin... |
DB01190 | DB11901 | 568 | 913 | [
"DDInter398",
"DDInter107"
] | Clindamycin | Apalutamide | Clindamycin is a semi-synthetic lincosamide antibiotic used in the treatment of a variety of serious infections due to susceptible microorganisms[L11599,L11596] as well as topically for acne vulgaris. It has a relatively narrow spectrum of activity that includes anaerobic bacteria as well as gram-positive cocci and bac... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
568,
24,
913
]
],
[
[
568,
24,
609
],
[
609,
24,
913
]
],
[
[
568,
63,
1091
],
[
1091,
24,
913
]
],
[
[
568,
63,
1056
],
[
1056,
... | [
[
[
"Clindamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Clindamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
... | Clindamycin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Clindamycin may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir... |
DB01242 | DB06595 | 1,237 | 1,491 | [
"DDInter410",
"DDInter1214"
] | Clomipramine | Midostaurin | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Moderate | 1 | [
[
[
1237,
24,
1491
]
],
[
[
1237,
62,
112
],
[
112,
23,
1491
]
],
[
[
1237,
63,
888
],
[
888,
24,
1491
]
],
[
[
1237,
24,
1342
],
[
1342,
... | [
[
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Clomipramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Clomipramine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and ... |
DB00930 | DB01022 | 166 | 1,484 | [
"DDInter432",
"DDInter1461"
] | Colesevelam | Phylloquinone | Colesevelam is a bile acid sequestrant. Colesevelam is used with exercise and diet changes (restriction of cholesterol and fat intake) to reduce the amount of cholesterol and certain fatty substances in the blood. It works by binding bile acids in the intestine. Bile acids are made when cholesterol is broken down in th... | Vitamin K1, also called phylloquinone or phytonadione, is a fat soluble vitamin.[L33319,L33345] Phylloquinone is a cofactor of the enzyme γ-carboxylase, which modifies and activates precursors to coagulation factors II, VII, IX, and X.[A234264,A234195,A234259] It is indicated in the treatment of coagulation disorders d... | Moderate | 1 | [
[
[
166,
24,
1484
]
],
[
[
166,
63,
126
],
[
126,
24,
1484
]
],
[
[
166,
24,
959
],
[
959,
21,
28746
],
[
28746,
60,
1484
]
],
[
[
166,
... | [
[
[
"Colesevelam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phylloquinone"
]
],
[
[
"Colesevelam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[... | Colesevelam may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Phylloquinone
Colesevelam may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipiz... |
DB01028 | DB01099 | 1,332 | 1,272 | [
"DDInter1179",
"DDInter744"
] | Methoxyflurane | Flucytosine | An inhalation anesthetic. Currently, methoxyflurane is rarely used for surgical, obstetric, or dental anesthesia. If so employed, it should be administered with nitrous oxide to achieve a relatively light level of anesthesia, and a neuromuscular blocking agent given concurrently to obtain the desired degree of muscular... | A fluorinated cytosine analog that is used as an antifungal agent. | Moderate | 1 | [
[
[
1332,
24,
1272
]
],
[
[
1332,
63,
485
],
[
485,
24,
1272
]
],
[
[
1332,
24,
1448
],
[
1448,
24,
1272
]
],
[
[
1332,
24,
712
],
[
712,
... | [
[
[
"Methoxyflurane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flucytosine"
]
],
[
[
"Methoxyflurane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
]... | Methoxyflurane may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Flucytosine
Methoxyflurane may cause a moderate interaction that could exacerbate diseases when taken with Streptomyc... |
DB00448 | DB01263 | 1,215 | 859 | [
"DDInter1022",
"DDInter1494"
] | Lansoprazole | Posaconazole | Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux ... | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Moderate | 1 | [
[
[
1215,
24,
859
]
],
[
[
1215,
6,
4973
],
[
4973,
45,
859
]
],
[
[
1215,
21,
30178
],
[
30178,
60,
859
]
],
[
[
1215,
24,
913
],
[
913,
... | [
[
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
]
],
[
[
"Lansoprazole",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compoun... | Lansoprazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Posaconazole (Compound)
Lansoprazole (Compound) causes Neck stiffness (Side Effect) and Neck stiffness (Side Effect) is caused by Posaconazole (Compound)
Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with A... |
DB00085 | DB11256 | 639 | 95 | [
"DDInter1384",
"DDInter1057"
] | Pancrelipase | Levomefolic acid | Pancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and proteases. These enzymes are extracted from porcine pancreatic glands. The pancrelipase mixture was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010. For further informa... | Levomefolic acid (INN) is the metabolite of folic acid (Vitamin B9) and it is a predominant active form of folate found in foods and in the blood circulation, accounting for 98% of folates in human plasma . It is transported across the membranes including the blood-brain barrier into various tissues where it plays an e... | Moderate | 1 | [
[
[
639,
24,
95
]
],
[
[
639,
24,
356
],
[
356,
23,
50
],
[
50,
23,
95
]
],
[
[
639,
24,
356
],
[
356,
35,
663
],
[
663,
24,
95
... | [
[
[
"Pancrelipase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomefolic acid"
]
],
[
[
"Pancrelipase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Folic acid"
]... | Pancrelipase may cause a moderate interaction that could exacerbate diseases when taken with Folic acid and Folic acid may cause a minor interaction that can limit clinical effects when taken with Sulfasalazine and Sulfasalazine may cause a minor interaction that can limit clinical effects when taken with Levomefolic a... |
DB01174 | DB12332 | 697 | 1,619 | [
"DDInter1442",
"DDInter1626"
] | Phenobarbital | Rucaparib | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
697,
24,
1619
]
],
[
[
697,
63,
222
],
[
222,
23,
1619
]
],
[
[
697,
25,
1135
],
[
1135,
23,
1619
]
],
[
[
697,
24,
259
],
[
259,
... | [
[
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
... | Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Phenobarbital may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cau... |
DB08908 | DB13915 | 713 | 689 | [
"DDInter564",
"DDInter146"
] | Dimethyl fumarate | Axicabtagene ciloleucel | Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis.[A253942,L43752] The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MM... | Axicabtagene ciloleucel is an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. The drug has a unique mechanism of action, as it utilizes the patient's own T cells, which play a central role in immune response to cancer. Once T-cells are collected from the patient, they are genetically engineered to express ant... | Moderate | 1 | [
[
[
713,
24,
689
]
],
[
[
713,
63,
599
],
[
599,
24,
689
]
],
[
[
713,
24,
270
],
[
270,
24,
689
]
],
[
[
713,
64,
976
],
[
976,
25,... | [
[
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Axicabtagene ciloleucel"
]
],
[
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"... | Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Axicabtagene ciloleucel
Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when tak... |
DB00976 | DB09039 | 1,056 | 1,670 | [
"DDInter1758",
"DDInter629"
] | Telithromycin | Eliglustat | Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with ... | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Major | 2 | [
[
[
1056,
25,
1670
]
],
[
[
1056,
25,
1135
],
[
1135,
62,
1670
]
],
[
[
1056,
25,
1409
],
[
1409,
24,
1670
]
],
[
[
1056,
63,
322
],
[
322... | [
[
[
"Telithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eliglustat"
]
],
[
[
"Telithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{... | Telithromycin may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Telithromycin may lead to a major life threatening interaction when taken with Apixaban and Apixaban may cause a moderate intera... |
DB00526 | DB01095 | 1,555 | 671 | [
"DDInter1355",
"DDInter769"
] | Oxaliplatin | Fluvastatin | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Fluvastatin belongs to a class of medications called statins and is used to r... | Moderate | 1 | [
[
[
1555,
24,
671
]
],
[
[
1555,
24,
788
],
[
788,
40,
671
]
],
[
[
1555,
24,
14
],
[
14,
63,
671
]
],
[
[
1555,
6,
7950
],
[
7950,
... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
],
... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin (Compound) resembles Fluvastatin (Compound)
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction... |
DB06209 | DB06603 | 256 | 39 | [
"DDInter1508",
"DDInter1387"
] | Prasugrel | Panobinostat | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversib... | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Major | 2 | [
[
[
256,
25,
39
]
],
[
[
256,
24,
578
],
[
578,
63,
39
]
],
[
[
256,
63,
1560
],
[
1560,
24,
39
]
],
[
[
256,
62,
1559
],
[
1559,
24... | [
[
[
"Prasugrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Prasugrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor... | Prasugrel may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Prasugrel may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pega... |
DB00059 | DB04896 | 1,560 | 901 | [
"DDInter1404",
"DDInter1220"
] | Pegaspargase | Milnacipran | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression [F3928, F3934, A175786, A175951]. Furthermore, in 2009 the US FDA approved milnacipran for the a... | Moderate | 1 | [
[
[
1560,
24,
901
]
],
[
[
1560,
24,
256
],
[
256,
63,
901
]
],
[
[
1560,
24,
500
],
[
500,
24,
901
]
],
[
[
1560,
63,
1648
],
[
1648,
... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
],
... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel and Prasugrel may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Enoxaparin and Eno... |
DB01128 | DB11581 | 918 | 1,456 | [
"DDInter204",
"DDInter1926"
] | Bicalutamide | Venetoclax | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small l... | Moderate | 1 | [
[
[
918,
24,
1456
]
],
[
[
918,
23,
1135
],
[
1135,
23,
1456
]
],
[
[
918,
24,
1476
],
[
1476,
63,
1456
]
],
[
[
918,
25,
1375
],
[
1375,
... | [
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
]
],
[
[
"Bicalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
... | Bicalutamide may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Venetoclax
Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatin... |
DB06788 | DB14509 | 1,616 | 1,399 | [
"DDInter864",
"DDInter1081"
] | Histrelin | Lithium carbonate | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-con... | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Moderate | 1 | [
[
[
1616,
24,
1399
]
],
[
[
1616,
24,
1385
],
[
1385,
24,
1399
]
],
[
[
1616,
63,
820
],
[
820,
24,
1399
]
],
[
[
1616,
62,
112
],
[
112,
... | [
[
[
"Histrelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Histrelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
],
... | Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide and Semaglutide may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine an... |
DB00012 | DB06404 | 1,535 | 1,514 | [
"DDInter479",
"DDInter869"
] | Darbepoetin alfa | Human C1-esterase inhibitor | Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. | C1 Esterase Inhibitor (Human) is composed of purified endogenous complement component-1 esterase inhibitor (hC1INH) isolated from human plasma. The primary function of endogenous C1INH is to regulate the activation of the complement and contact system pathways.[L16586, L16606] This drug is indicated for prophylaxis and... | Moderate | 1 | [
[
[
1535,
24,
1514
]
],
[
[
1535,
25,
350
],
[
350,
64,
1514
]
],
[
[
1535,
25,
770
],
[
770,
25,
1514
]
],
[
[
1535,
25,
350
],
[
350,
... | [
[
[
"Darbepoetin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human C1-esterase inhibitor"
]
],
[
[
"Darbepoetin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carfilzomib"
... | Darbepoetin alfa may lead to a major life threatening interaction when taken with Carfilzomib and Carfilzomib may lead to a major life threatening interaction when taken with Human C1-esterase inhibitor
Darbepoetin alfa may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may lea... |
DB09312 | DB10795 | 967 | 221 | [
"DDInter103",
"DDInter1486"
] | Antilymphocyte immunoglobulin (horse) | Poliovirus type 1 antigen (formaldehyde inactivated) | Equine anti-thymocyte globulin is composed of purified gamma globulin containing primarily IgG against human thymus lymphocytes. It is formed by inoculating a horse with an antigen (human thymoyctes) which then induces the horse immune system's B-lymphocytes to produce IgG immunoglobulins specific for that antigen. The... | Poliovirus type 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 1. The vaccine contains purified and inactivated poliovirus type 1 that were grown from a c... | Moderate | 1 | [
[
[
967,
24,
221
]
],
[
[
967,
64,
581
],
[
581,
24,
221
]
],
[
[
967,
63,
599
],
[
599,
24,
221
]
],
[
[
967,
24,
1531
],
[
1531,
2... | [
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may lead to a major life... | Antilymphocyte immunoglobulin (horse) may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Antilymphocyte immunoglobulin (horse) may cause a moderate... |
DB01069 | DB01359 | 401 | 729 | [
"DDInter1533",
"DDInter1417"
] | Promethazine | Penbutolol | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. Penbutolol also demonstrates high... | Moderate | 1 | [
[
[
401,
24,
729
]
],
[
[
401,
63,
461
],
[
461,
1,
729
]
],
[
[
401,
24,
699
],
[
699,
40,
729
]
],
[
[
401,
21,
28698
],
[
28698,
... | [
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Penbutolol"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
],
[
... | Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol (Compound) resembles Penbutolol (Compound)
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Nadolol and Nadolol (Compound) resembles Penbutolol (Compound)
Prometha... |
DB00227 | DB00563 | 1,463 | 663 | [
"DDInter1098",
"DDInter1174"
] | Lovastatin | Methotrexate | Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of _Aspergillus terreus_. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disea... | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Moderate | 1 | [
[
[
1463,
24,
663
]
],
[
[
1463,
6,
4973
],
[
4973,
45,
663
]
],
[
[
1463,
7,
2903
],
[
2903,
46,
663
]
],
[
[
1463,
18,
7448
],
[
7448,
... | [
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
]
],
[
[
"Lovastatin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",... | Lovastatin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Methotrexate (Compound)
Lovastatin (Compound) upregulates MMP1 (Gene) and MMP1 (Gene) is upregulated by Methotrexate (Compound)
Lovastatin (Compound) downregulates MOK (Gene) and MOK (Gene) is upregulated by Methotrexate (Compound)
Lovastatin (Compou... |
DB00241 | DB12001 | 288 | 564 | [
"DDInter257",
"DDInter7"
] | Butalbital | Abemaciclib | Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervou... | Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the trea... | Moderate | 1 | [
[
[
288,
24,
564
]
],
[
[
288,
1,
536
],
[
536,
24,
564
]
],
[
[
288,
24,
868
],
[
868,
24,
564
]
],
[
[
288,
23,
1101
],
[
1101,
24... | [
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
]
],
[
[
"Butalbital",
"{u} (Compound) resembles {v} (Compound)",
"Secobarbital"
],
[
"Secobarbital",
"{u} may cause a mo... | Butalbital (Compound) resembles Secobarbital (Compound) and Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction tha... |
DB00033 | DB11995 | 342 | 1,634 | [
"DDInter949",
"DDInter143"
] | Interferon gamma-1b | Avatrombopag | Human Interferon gamma-1b (140 residues), produced from E. coli. Production of Actimmune is achieved by fermentation of a genetically engineered Escherichia coli bacterium containing the DNA which encodes for the human protein. Purification of the product is achieved by conventional column chromatography. The sequence ... | Avatrombopag (_Doptelet_), is an orally administered, small molecule thrombopoietin receptor (c-Mpl) agonist that increases platelet number without increasing platelet activation,[A33097,L2824] thereby decreasing the need for blood transfusions. Patients with thrombocytopenia and chronic liver disease often require pla... | Moderate | 1 | [
[
[
342,
24,
1634
]
],
[
[
342,
24,
1613
],
[
1613,
24,
1634
]
],
[
[
342,
24,
1613
],
[
1613,
63,
1622
],
[
1622,
24,
1634
]
],
[
[
342,
... | [
[
[
"Interferon gamma-1b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avatrombopag"
]
],
[
[
"Interferon gamma-1b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginte... | Interferon gamma-1b may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Avatrombopag
Interferon gamma-1b may cause a moderate interaction that could exacerbate dise... |
DB00169 | DB01320 | 386 | 651 | [
"DDInter367",
"DDInter783"
] | Cholecalciferol | Fosphenytoin | Vitamin D, in general, is a secosteroid generated in the skin when 7-dehydrocholesterol located there interacts with ultraviolet irradiation - like that commonly found in sunlight. Both the endogenous form of vitamin D (that results from 7-dehydrocholesterol transformation), vitamin D3 (cholecalciferol), and the plant-... | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Moderate | 1 | [
[
[
386,
24,
651
]
],
[
[
386,
24,
362
],
[
362,
1,
651
]
],
[
[
386,
6,
6017
],
[
6017,
45,
651
]
],
[
[
386,
25,
1041
],
[
1041,
2... | [
[
[
"Cholecalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Cholecalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
... | Cholecalciferol may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Fosphenytoin (Compound)
Cholecalciferol (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Fosphenytoin (Compound)
Cholecalciferol may lead to a major life threatening i... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.